Subtitle: Chromatin Remodeling & Epigenetic Targeting Assay Reagents for Nucleosome Dynamics Research
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C16 structural and functional studies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C16 Recombinant Protein (WT & C16 Mutants) High purity (>95%), Sequence Verified. E. coli expressed for unmodified baseline or HEK293 for native context. Endotoxin <0.1 EU/µg. |
View H4C16 Products |
| Gene Delivery | H4C16 Lentivirus Particles Full-length ORF with N-terminal FLAG tag for nucleosome assembly studies. High titer (>10^8 TU/ml). |
View H4C16 Products |
| Validator | H4C16 siRNA Set (3 unique targets) For knockdown verification and specificity controls. Chemically synthesized, HPLC purified. |
View H4C16 Products |
| Structural Analysis | Nucleosome Assembly Kit (H4C16 + H2A/H2B/H3) Reconstituted octamers for chromatin remodeling assays. |
View H4C16 Products |
| Related Target: H3K27 | Histone H3 (K27 Mutants) Synergistic epigenetic pathway partner for polycomb repressive complex studies. |
View H3K27 Products |
| Related Target: BRD4 | Bromodomain Containing Protein 4 Histone reader protein interacting with acetylated histone H4 tails. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleosome Reconstitution Purity | Ultra-pure H4C16 (>98% by SDS-PAGE, endotoxin <0.1 EU/µg) ensures consistent octamer assembly without aggregation artifacts |
| C16 Oxidation State Control | Site-specific C16S/C16A mutants available for studying redox-sensitive chromatin dynamics; anaerobic preparation option |
| Off-target Epitope Screening | Pan-Histone H4 antibody controls and H4C16-specific peptide competitors for assay validation |
| Chromatin Binding Specificity | Validated siRNA for target engagement confirmation in ChIP and FRAP assays |
Live H4C16 R&D Tracker
Monitor the latest developments in chromatin-targeted therapies and structural epigenetics:
Global Clinical Landscape & Future Outlook
The investigation of H4C16 as a structural determinant of chromatin compaction represents a paradigm shift toward targeting histone folding cores rather than modification tails. As the field moves from tail-focused epigenetic drugs (HDAC inhibitors, BET inhibitors) to structural chromatin disruptors, the demand for high-fidelity histone proteins and nucleosome assembly systems has intensified.
Emerging research indicates that C16-mediated zinc coordination in the histone fold is critical for nucleosome stability, making H4C16 a potential vulnerability point in chromatin remodeling-driven cancers. The next wave of R&D focuses on allosteric modulators that disrupt histone-histone interactions within the octamer core.
Competitive Modality & Indication Snapshot
| Modality | Research Application | Key Indications | Critical Assay Need |
|---|---|---|---|
| Structural Modulators | Academic / Biotech | Chromatin Remodeling Cancers | Nucleosome Stability Assay (Need high-purity WT vs C16 mutants) |
| Peptide Inhibitors | Early Discovery | Epigenetic Dysregulation | Octamer Disassembly Kinetics (Need homogenous H4C16 preparations) |
| Targeted Protein Degradation | PROTAC Development | Oncology | Intracellular Histone Turnover (Need validated siRNA controls) |